Glaucoma Devices: Progress On Multiple Fronts
Recent progress on the US regulatory front is generating renewed interest in device-based glaucoma therapies, which potentially could grow to a multibillion-dollar industry. The list of companies targeting this space continues to expand, as does the variety of potential device-based solutions: the current pipeline includes several innovative and less invasive products and technologies designed to improve surgical outcomes, a growing number of advanced drug-delivery inserts to address the patient noncompliance issue that is so common in this arena, and some unique patient monitoring devices.
You may also be interested in...
Nicox of France pins hopes on glaucoma drug Vesneo – targeted for FDA submission in second quarter 2015 – and recent purchase of Aciex Therapeutics to build itself into an international ophthalmic player and ‘partner of choice’ in Europe.
This article was adapted from "In Glaucoma, Devices Go Eye-to-Eye with Drugs," in the September 2010 issue of Start-Up.
Drug therapy has dominated glaucoma management for decades, but novel device technologies are shifting the way this disease is managed, adding promising new options to the previously limited treatment continuum. For companies active in this field, along with an increasing number of VCs targeting ophthalmology, this shift marks the beginning of a tremendous new opportunity--one that will involve challenges and risks, but that also offers a huge payoff for those able to provide the right technology at the right time.